Related Experiment Video
Updated: Jun 17, 2026
Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3
Published on: December 27, 2010
Tropism testing in the clinical management of HIV-1 infection
Nina H Lin1, Daniel R Kuritzkes
1Infectious Diseases Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
Purpose Of Review:
A variety of methods are available to determine HIV-1 co-receptor usage, commonly referred to as viral tropism. This article reviews recent data on phenotypic and genotypic assays of HIV-1 tropism.
Recent Findings:
Tropism assays are used to determine co-receptor usage of HIV-1 in patients who may be candidates for treatment with CCR5 antagonists. Phenotypic assays are used most often in the clinical trials of CCR5 antagonists, and are considered the 'gold standard' for comparison with other methods of tropism testing. Enhancements have allowed detection of a lower threshold of minor CXCR4-using species. When compared with phenotypic assays, genotypic methods have poor sensitivity but good specificity at detecting CXCR4-using HIV-1. Preliminary results from a recent comparative study suggest that some genotypic methods may perform as well as phenotypic tests in predicting virologic response to CCR5 antagonists. Several studies show that tropism testing may provide useful prognostic information regarding the risk of disease progression.
Summary:
Understanding the characteristic of different tropism assays is important for their clinical use. Although phenotypic testing currently is favored, genotypic assays may be a suitable alternative in appropriate settings.
Insights
Accurate HIV-1 tropism testing is crucial for selecting CCR5 antagonist therapy. Phenotypic assays are the gold standard, but genotypic methods show promise as alternatives for predicting treatment response and disease progression.
Area of Science:
- Virology
- Infectious Diseases
- Molecular Biology
Background:
- HIV-1 co-receptor usage, or viral tropism, dictates disease progression and treatment options.
- CCR5 antagonists are a key therapeutic class for specific HIV-1 patient populations.
- Accurate tropism determination is essential for guiding treatment decisions.
Purpose of the Study:
- To review recent advancements in HIV-1 tropism assays.
- To compare the performance of phenotypic and genotypic tropism testing methods.
- To assess the clinical utility of tropism testing in predicting treatment outcomes and disease progression.
Main Methods:
- Review of recent scientific literature on HIV-1 tropism assays.
- Analysis of data from phenotypic and genotypic tropism testing studies.
- Comparison of assay sensitivity, specificity, and predictive value for CCR5 antagonist therapy.
Main Results:
- Phenotypic assays are the current gold standard for tropism testing, with enhanced versions detecting low-frequency CXCR4-using variants.
- Genotypic assays demonstrate good specificity but lower sensitivity for detecting CXCR4-using HIV-1 compared to phenotypic methods.
- Emerging data suggest genotypic assays may predict virologic response to CCR5 antagonists similarly to phenotypic tests.
- Tropism testing offers valuable prognostic information regarding HIV-1 disease progression risk.
Conclusions:
- Understanding the nuances of different tropism assays is vital for effective clinical application.
- While phenotypic testing remains preferred, genotypic assays represent a viable alternative in specific clinical scenarios.
- Tropism testing plays a significant role in personalized HIV-1 treatment strategies.
